WF2304-A172401 Multi-Site Cancer

Full Clinical Trial Name

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Clinical Trial

  • Cancer

Patient Type

Adult
Doctor(s) running this study
Maged F. Khalil, MD
Location(s):
Call 610-402-9543
Search more clinical trials

Description

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

Eligibility

Inclusion Criteria
  • Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer.
  • Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
  • Participants must be able to comprehend English or Spanish (for survey completion).
  • Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
  • Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
Exclusion Criteria
  • Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
  • Participants with known pregnancy.

Doctor(s) running this study